10-K: Philip Morris International Reports 2024 Annual Results, Highlights Smoke-Free Transformation

Philip Morris International's 2024 annual report showcases a company in transition, emphasizing smoke-free products and navigating a complex global landscape.

Summary

• Philip Morris International (PMI) released its Form 10-K for the fiscal year ended December 31, 2024.
• The company's total shipment volume, including cigarettes and heated tobacco units, increased by 2.5% in 2024 to 756.6 billion units.
• Heated tobacco unit shipment volume reached 139.7 billion units in 2024, up from 125.3 billion units in 2023.
• Cigarette shipment volume of PMI's principal brand, Marlboro, increased by 3.7% in 2024.
• Net revenues increased by 7.7% to $37.9 billion, with net revenues excluding currency and acquisitions increasing by 10.1%.
• The company reported a non-cash impairment charge of $2,316 million related to its equity investment in Rothmans, Benson & Hedges (RBH).
• Diluted earnings per share (EPS) decreased by 10.0% to $4.52.
• PMI expects total cigarette and smoke-free product shipment volume growth of up to 2% in 2025, driven by smoke-free products volume growth of 12% to 14%.
• The company anticipates nicotine pouch shipment volume in the U.S. of 780 to 820 million cans in 2025.
• PMI estimates its 2025 effective tax rate will be approximately 22.5% to 23.5%, excluding discrete tax events.
• The company is progressing with plans to build manufacturing capacity for smoke-free products and optimize its manufacturing infrastructure.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are positive aspects like revenue growth and progress in smoke-free products, the significant impairment charge and EPS decline temper the overall outlook.

Positives

• Total shipment volume increased, driven by heated tobacco units.
• Net revenues increased, reflecting favorable pricing and volume/mix.
• Marlboro cigarette shipment volume increased.
• Smoke-free products are expanding into more markets.
• The company is investing in new production facilities and optimizing its manufacturing infrastructure.

Negatives

• Diluted EPS decreased by 10.0% to $4.52.
• The company recorded a $2.316 billion non-cash impairment charge related to its RBH equity investment.
• The company faces risks related to the war in Ukraine and regulatory constraints in Russia.
• The company faces potential tax liabilities and challenges in various markets.

Risks

• The company may be unsuccessful in its attempts to introduce, commercialize, and grow smoke-free products in existing and new markets.
• Consumption of tax-paid cigarettes continues to decline in many of PMI's markets.
• The company's business, results of operations, cash flows and financial position may be adversely impacted by the continuation and consequences of the war in Ukraine.
• The company faces intense competition, and its failure to compete effectively could have a material adverse effect on its profitability and results of operations.
• The company's revenues may be materially adversely affected as a result of counterfeiting, contraband, cross-border purchases, illicit products, non-tax-paid volume produced by local manufacturers and other non-compliant or illicit cigarettes or smoke-free products.

Future Outlook

PMI expects total cigarette and smoke-free product shipment volume growth of up to 2% in 2025, driven by smoke-free products volume growth of 12% to 14%. The company also expects nicotine pouch shipment volume in the U.S. of 780 to 820 million cans in 2025.

Industry Context

The document highlights the ongoing shift in the tobacco industry towards smoke-free products, with PMI actively investing in and commercializing these alternatives. The regulatory landscape, particularly the influence of the FCTC and actions by the FDA, plays a crucial role in shaping the industry's future.

Comparison to Industry Standards

• The report mentions key competitors such as Altria Group, British American Tobacco plc, Japan Tobacco Inc., and Imperial Brands plc.
• PMI's strategy of transitioning to smoke-free products aligns with the broader industry trend of adapting to changing consumer preferences and regulatory pressures.
• The company's investment of over $14 billion in smoke-free product development demonstrates a significant commitment compared to some competitors.
• The FDA authorizations for IQOS and ZYN products provide a competitive advantage in the U.S. market.

Legal Proceedings

• The company is involved in various legal proceedings, including tobacco-related litigation and challenges related to smoke-free products.
• The company is subject to governmental investigations on a range of matters, including tax, customs, antitrust, advertising, and labor practices.

Related Party Transactions

• The report discloses transactions with related parties, including Megapolis Distribution B.V. and other equity method investees.

Stakeholder Impact

• Shareholders may be concerned about the EPS decline and impairment charge.
• Employees may be affected by restructuring activities and changes in manufacturing operations.
• Customers are expected to benefit from the availability of smoke-free alternatives.
• Suppliers may be impacted by changes in sourcing strategies and contract terminations.

Next Steps

• PMI will continue to monitor the situation in Russia and develop contingency plans.
• The company will continue to optimize its manufacturing infrastructure and expand its commercialization activities for new products and markets.
• PMI will continue to monitor the evolving regulatory landscape and advocate for science-based regulatory frameworks for smoke-free products.

Key Dates

Keywords

smoke-free products, heated tobacco units, net revenues, shipment volume, financial results, Philip Morris International, impairment, cigarettes, market share, ZYN, IQOS